STOCK TITAN
  1. Home
  2. Sec-filings
  3. VRXA
  4. [6-K] Veraxa Biotech AG - Post de-SPAC Current Report (Foreign Issuer)

Veraxa Biotech appoints Raju Willener CFO

Veraxa Biotech AG appoints veteran finance executive Raju Willener as CFO and principal financial officer to support its BiTAC-based oncology pipeline and capital markets strategy.

Filing Impact
(Neutral)
Filing Sentiment
(Neutral)
Form Type
6-K

Rhea-AI Filing Summary

Veraxa Biotech AG (VRXA) announced the appointment of Raju Willener as Chief Financial Officer, effective September 4, 2026. He will serve as the company’s principal financial and accounting officer and report to CEO and Co-Founder Christoph Antz, Ph.D.

The company highlights that Mr. Willener brings more than three decades of international experience across investment banking, corporate finance, asset management and strategic leadership, including oversight of investment portfolios exceeding CHF 30 billion in assets under management. Veraxa positions this hire as strengthening its capital markets and financial strategy capabilities as it advances its BiTAC-based oncology pipeline. The company also acknowledges the contributions of former CFO Carl von Halem.

Positive

  • None.

Negative

  • None.
Years of experience More than 30 years International finance and leadership experience of new CFO Raju Willener
Assets under management overseen Over CHF 30 billion Investment portfolios previously overseen by Raju Willener at global financial institutions
Effective date of CFO appointment September 4, 2026 Appointment of Raju Willener as Chief Financial Officer
BiTAC medical
"advancement of the Company’s pipeline of potential best-in-class therapies led by its BiTAC"
conditionally active T cell engagers medical
"advancing its pipeline of conditionally active T cell engagers (BiTAC-TCEs)"
Conditionally active T cell engagers are engineered biotherapeutics, usually bispecific proteins, that bind a cancer cell target and a T cell but only become fully active under specific conditions found in tumors (for example low pH, specific enzymes, or unique surface markers). They matter to investors because the conditional switch aims to concentrate immune attack on tumors while reducing side effects elsewhere, affecting clinical risk, regulatory review, and commercial appeal.
bispecific antibody-drug conjugates medical
"pipeline of conditionally active T cell engagers (BiTAC-TCEs), bispecific antibody-drug conjugates (bsADCs)"
A bispecific antibody-drug conjugate is a targeted cancer therapy that combines an antibody engineered to bind two different biological targets with a potent drug payload attached to that antibody. Think of it like a delivery truck with two GPS locks that can home in on two separate addresses and release a toxic package only where both signals are present. Investors watch them because this dual-targeting design can change a drug’s therapeutic reach, safety profile, and commercial potential compared with single-target therapies, affecting development risk and market value.
New Approach Methodologies medical
"implemented FDA-aligned New Approach Methodologies across all preclinical programs"
New approach methodologies are modern ways to evaluate the safety and effects of chemicals, drugs, and products using lab-grown cells, computer models, and fast automated tests instead of traditional animal studies. They matter to investors because these methods can speed up development, lower testing costs, reduce regulatory risk, and create business opportunities for companies that provide or use them—think of replacing slow road tests with a faster, cheaper simulator.
forward-looking statements regulatory
"This press release may contain “forward-looking statements” within the meaning"
Forward-looking statements are predictions or plans that companies share about what they expect to happen in the future, like estimating sales or profits. They matter because they help investors understand a company's outlook, but since they are based on guesses and assumptions, they can sometimes be wrong.

FAQ

What executive change did Veraxa Biotech AG (VRXA) announce in this Form 6-K?
Veraxa Biotech AG announced the appointment of Raju Willener as Chief Financial Officer, effective immediately. He will act as the company’s principal financial officer and principal accounting officer and report to CEO and Co-Founder Christoph Antz, Ph.D..

What is the background of new VRXA CFO Raju Willener?
Raju Willener is described as an accomplished finance executive with more than three decades of international experience in investment banking, corporate finance, asset management and strategic leadership, including senior roles such as CFO, Chief Investment Officer, Country Head and Head of Corporate Finance across the U.S., Europe and Asia.

What was Raju Willener’s role before joining Veraxa Biotech AG (VRXA)?
Before joining Veraxa, Raju Willener worked at Exentis Group AG, first as Director of Corporate Development and then as Chief Financial Officer in 2025, where he led M&A initiatives, financial strategy and key corporate functions.

How extensive is the capital markets experience of VRXA’s new CFO?
The company states that Mr. Willener has held senior executive and investment leadership positions overseeing investment portfolios exceeding CHF 30 billion in assets under management, with responsibilities spanning corporate finance, capital markets and investor relations.

What is Veraxa Biotech AG’s core focus as described in the 6-K filing?
Veraxa is described as a leading developer of next-generation antibody-based cancer therapies, advancing conditionally active T cell engagers (BiTAC-TCEs), bispecific antibody-drug conjugates and proprietary BiTAC formats into clinical development, supported by FDA-aligned New Approach Methodologies across preclinical programs.

What qualifications does the new VRXA CFO hold?
The filing states that Mr. Willener holds an MBA and a Master’s degree in Accounting and Finance and is qualified in Financial Risk Management, supporting his role overseeing Veraxa Biotech AG’s financial and capital markets strategy.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 6-K: How Foreign Companies Report to the SEC →
See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google
Add on Google

 

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, DC 20549

 

 

 

FORM 6-K

 

 

 

REPORT OF FOREIGN PRIVATE ISSUER

PURSUANT TO RULE 13A-16 OR 15D-16

OF THE SECURITIES EXCHANGE ACT OF 1934

 

For the month of September 2026

 

Commission File Number: 001-43342

 

 

 

Veraxa Biotech AG

 

 

 

Talacker 35

8001 Zurich, Switzerland

(Address of principal executive office)

 

 

 

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.

 

Form 20-F ☒          Form 40-F ☐

 

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1): ☐

 

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7): ☐

 

 

 

 

 

 

Chief Financial Officer Appointment

 

On September 4, 2026, Veraxa Biotech AG (the “Company”) issued a press release announcing the appointment of Raju Willener as Chief Financial Officer (CFO). In his position as CFO, Mr. Willener will act as the Company’s principal financial officer and principal accounting officer.

 

Mr. Willener is an accomplished finance executive with more than three decades of international experience spanning investment banking, corporate finance, asset management and strategic leadership. Throughout his career, he has held senior roles, including Chief Financial Officer, Chief Investment Officer, Country Head and Head of Corporate Finance across the U.S., Europe and Asia. Prior to joining VERAXA, Mr. Willener served as Director of Corporate Development at Exentis Group AG, before being appointed Chief Financial Officer in 2025, where he led M&A initiatives, financial strategy and key corporate functions. Earlier in his career, Mr. Willener held senior executive and investment leadership positions at top-tier global financial institutions and investment firms, with responsibilities spanning corporate finance, capital markets, investor relations and the oversight of investment portfolios exceeding CHF 30 billion in assets under management. Mr. Willener holds an MBA and a Master’s degree in Accounting and Finance and is qualified in Financial Risk Management.

 

A copy of the press release is attached hereto as Exhibit 99.1 and is incorporated herein by reference.

 

EXHIBIT INDEX

 

Exhibit   Description of Exhibit
99.1   Press Release dated September 4, 2026

 

1

 

 

SIGNATURE

 

Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

 

  VERAXA BIOTECH AG
   
Date: September 4, 2026 By: /s/ Christoph Antz
  Name:  Christoph Antz
  Title: Chief Executive Officer

 

  By: /s/ Oliver Baumann
  Name:  Oliver Baumann
  Title: Chairman of the Board of Directors

 

2

 

Exhibit 99.1

 

 

 

Press Release

 

VERAXA Biotech Appoints Raju Willener as Chief Financial Officer

 

Mr. Willener brings more than three decades of global capital markets and corporate finance experience to support advancement of the Company’s pipeline of potential best-in-class therapies led by its BiTAC® platform

 

ZURICH, SWITZERLAND – September 4, 2026 – VERAXA Biotech AG (NASDAQ: VRXA; “VERAXA” or the “Company”), a leading developer of next-generation antibody-based cancer therapies, today announced the appointment of Raju Willener as Chief Financial Officer (CFO), effective immediately. Mr. Willener will report to Christoph Antz, Ph.D., Chief Executive Officer and Co-Founder. Mr. Willener brings more than three decades of financial leadership across global capital markets and every stage of the biopharmaceutical development process.

 

“We are delighted to welcome Raju at an important stage in the Company’s evolution,” said Christoph Antz, Ph.D., CEO and Co-Founder of VERAXA. “His extensive experience in global capital markets, corporate finance, M&A and investment management adds significant financial and strategic depth to our leadership team. As we advance our proprietary BiTAC® technology platform and growing oncology pipeline, Raju’s expertise will be highly valuable in optimizing our capital strategy, evaluating strategic opportunities and supporting disciplined execution and long-term shareholder value creation. At the same time, we would like to extend a special thank you to Carl von Halem for his outstanding and great support as the former CFO of VERAXA.”

 

Mr. Willener is an accomplished finance executive with more than three decades of international experience spanning investment banking, corporate finance, asset management and strategic leadership. Throughout his career, he has held senior roles, including Chief Financial Officer, Chief Investment Officer, Country Head and Head of Corporate Finance across the U.S., Europe and Asia.

 

Prior to joining VERAXA, Mr. Willener served as Director of Corporate Development at Exentis Group AG, before being appointed Chief Financial Officer in 2025, where he led M&A initiatives, financial strategy and key corporate functions.

 

Earlier in his career, Mr. Willener held senior executive and investment leadership positions at top-tier global financial institutions and investment firms, with responsibilities spanning corporate finance, capital markets, investor relations and the oversight of investment portfolios exceeding CHF 30 billion in assets under management.

 

Mr. Willener holds an MBA and a Master’s degree in Accounting and Finance and is qualified in Financial Risk Management.

 

“VERAXA has built a highly differentiated technology platform and a compelling oncology pipeline at an important stage of its development,” said Raju Willener. “I am excited to join the Company and work alongside Christoph and the leadership team to further strengthen VERAXA’s financial and capital markets strategy, support disciplined capital allocation and pursue strategic opportunities that can accelerate development of a differentiated pipeline and create sustainable long-term value for shareholders.”

 

 

VERAXA Biotech AG / Talacker 35 / CH-8001 Zürich

VERAXA Biotech GmbH / Im Neuenheimer Feld 584 / 69120 Heidelberg

 

 

 

About VERAXA Biotech AG (NASDAQ: VRXA)

 

VERAXA is building a premier engine for the discovery and development of next-generation antibody-based cancer therapeutics, powered by a suite of transformative technologies and guided by rigorous quality-by-design principles. The Company is rapidly advancing its pipeline of conditionally active T cell engagers (BiTAC-TCEs), bispecific antibody-drug conjugates (bsADCs), and proprietary BiTAC formats into clinical development. Uniquely, VERAXA has implemented FDA-aligned New Approach Methodologies across all preclinical programs, enabling faster clinical advancement while reducing reliance on animal testing. Founded on scientific breakthroughs from the European Molecular Biology Laboratory (EMBL), a world-renowned institution for pioneering life science research, VERAXA combines innovation with responsible research practices.

 

For regular updates about VERAXA Biotech, visit www.veraxa.com or follow us on LinkedIn, X (formerly known as Twitter) and Bluesky.

 

BiTAC® is a registered trademark of VERAXA Biotech GmbH.

 

Forward-looking Statements

 

This press release may contain “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. All statements that address activities, events, or developments that VERAXA Biotech AG (the “Company”) intends, expects, plans, projects, believes, or anticipates will or may occur in the future are forward-looking statements, including the Company’s ability to identify, secure, and maintain key personnel and the ability of its technological platform to produce transformative therapeutics. Such forward-looking statements are based on current expectations and involve inherent risks and uncertainties, including factors that could delay, divert, or change any of them, and could cause actual outcomes and results to differ materially from current expectations. No forward-looking statement can be guaranteed. Forward-looking statements contained in this press release should be evaluated together with the many uncertainties that affect the Company’s business, particularly those identified or referenced in the risk factors section of the Company’s most recent Annual Report on Form 20-F and any subsequent reports on Form 6-K. These documents are available from the Securities and Exchange Commission, the Company website or from Company Investor Relations.

 

In addition, any information contained in this press release was current as of the date presented and should not be relied upon as representing our estimates as of any subsequent date. While we may elect to update forward-looking statements at some point in the future, we specifically disclaim any obligation to do so, even if our estimates change, whether as a result of new information, future events, or otherwise. Consequently, the Company will not update the information contained in this press release, and investors should not rely upon the information as current or accurate after the presentation date.

 

 

VERAXA Biotech AG / Talacker 35 / CH-8001 Zürich

VERAXA Biotech GmbH / Im Neuenheimer Feld 584 / 69120 Heidelberg

 

2

 

 

Contact

 

VERAXA Biotech AG – Corporate
Christoph Antz, Ph.D.
Chief Executive Officer, Co-Founder
investors@veraxa.com

 

For Media and Investors – U.S.
Brandon Weiner
ICR Healthcare
VERAXA@icrhealthcare.com

 

For Media and Investors – EU
Mario Brkulj
investors@veraxa.com

 

 

VERAXA Biotech AG / Talacker 35 / CH-8001 Zürich

VERAXA Biotech GmbH / Im Neuenheimer Feld 584 / 69120 Heidelberg

 

3

Source: View Original Filing on SEC EDGAR

Filing Exhibits & Attachments

2 documents

Press Releases